LUMENHANCE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Lumenhance, and when can generic versions of Lumenhance launch?
Lumenhance is a drug marketed by Bracco and is included in one NDA.
The generic ingredient in LUMENHANCE is manganese chloride tetrahydrate. There are five drug master file entries for this compound. Additional details are available on the manganese chloride tetrahydrate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LUMENHANCE?
- What are the global sales for LUMENHANCE?
- What is Average Wholesale Price for LUMENHANCE?
Summary for LUMENHANCE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | LUMENHANCE at DailyMed |
US Patents and Regulatory Information for LUMENHANCE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bracco | LUMENHANCE | manganese chloride tetrahydrate | FOR SOLUTION;ORAL | 020686-001 | Dec 19, 1997 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
